Systemic Levels of Pro-Inflammatory Cytokines and Post-Treatment Modulation in Tuberculous Lymphadenitis

Overview

Journal Trop Med Infect Dis

Specialty Infectious Diseases

Date 2023 Mar 28

PMID 36977151

Authors

Gokul Raj Kathamuthu

Kadar Moideen

Rathinam Sridhar

Dhanaraj Baskaran

Subash Babu

Affiliations

Soon will be listed here.

Abstract

Pro-inflammatory cytokines are potent stimulators of inflammation and immunity and markers of infection severity and bacteriological burden in pulmonary tuberculosis (PTB). Interferons could have both host-protective and detrimental effects on tuberculosis disease. However, their role has not been studied in tuberculous lymphadenitis (TBL). Thus, we evaluated the systemic pro-inflammatory (interleukin (IL)-12, IL-23, interferon (IFN)α, and IFNβ) cytokine levels in TBL, latent tuberculosis (LTBI), and healthy control (HC) individuals. In addition, we also measured the baseline (BL) and post-treatment (PT) systemic levels in TBL individuals. We demonstrate that TBL individuals are characterized by increased pro-inflammatory (IL-12, IL-23, IFNα, IFNβ) cytokines when compared to LTBI and HC individuals. We also show that after anti-tuberculosis treatment (ATT) completion, the systemic levels of pro-inflammatory cytokines were significantly modulated in TBL individuals. A receiver operating characteristic (ROC) analysis revealed IL-23, IFNα, and IFNβ significantly discriminated TBL disease from LTBI and/or HC individuals. Hence, our study demonstrates the altered systemic levels of pro-inflammatory cytokines and their reversal after ATT, suggesting that they are markers of disease pathogenesis/severity and altered immune regulation in TBL disease.

References

Chaussabel D, Tolouei Semnani R, McDowell M, Sacks D, Sher A, Nutman T . Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood. 2003; 102(2):672-81. DOI: 10.1182/blood-2002-10-3232. View

Khader S, Cooper A . IL-23 and IL-17 in tuberculosis. Cytokine. 2008; 41(2):79-83. PMC: 2266085. DOI: 10.1016/j.cyto.2007.11.022. View

Domingo-Gonzalez R, Prince O, Cooper A, Khader S . Cytokines and Chemokines in Mycobacterium tuberculosis Infection. Microbiol Spectr. 2016; 4(5). PMC: 5205539. DOI: 10.1128/microbiolspec.TBTB2-0018-2016. View

Henry C, Ornelles D, Mitchell L, Brzoza-Lewis K, Hiltbold E . IL-12 produced by dendritic cells augments CD8+ T cell activation through the production of the chemokines CCL1 and CCL17. J Immunol. 2008; 181(12):8576-84. PMC: 2716729. DOI: 10.4049/jimmunol.181.12.8576. View

Dorhoi A, Kaufmann S . Perspectives on host adaptation in response to Mycobacterium tuberculosis: modulation of inflammation. Semin Immunol. 2014; 26(6):533-42. DOI: 10.1016/j.smim.2014.10.002. View

Snyder D, Hedges J, Jutila M . Getting "Inside" Type I IFNs: Type I IFNs in Intracellular Bacterial Infections. J Immunol Res. 2017; 2017:9361802. PMC: 5424489. DOI: 10.1155/2017/9361802. View

Wozniak T, Ryan A, Britton W . Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J Immunol. 2006; 177(12):8684-92. DOI: 10.4049/jimmunol.177.12.8684. View

Kovarik P, Castiglia V, Ivin M, Ebner F . Type I Interferons in Bacterial Infections: A Balancing Act. Front Immunol. 2017; 7:652. PMC: 5183637. DOI: 10.3389/fimmu.2016.00652. View

Mayer-Barber K, Barber D . Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. Cold Spring Harb Perspect Med. 2015; 5(12). PMC: 4665043. DOI: 10.1101/cshperspect.a018424. View

10.

Aman M, Tretter T, Eisenbeis I, Bug G, Decker T, Aulitzky W . Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood. 1996; 87(11):4731-6. View

11.

Hermann P, Rubio M, Nakajima T, Delespesse G, Sarfati M . IFN-alpha priming of human monocytes differentially regulates gram-positive and gram-negative bacteria-induced IL-10 release and selectively enhances IL-12p70, CD80, and MHC class I expression. J Immunol. 1998; 161(4):2011-8. View

12.

Handa U, Mundi I, Mohan S . Nodal tuberculosis revisited: a review. J Infect Dev Ctries. 2012; 6(1):6-12. DOI: 10.3855/jidc.2090. View

13.

Kathamuthu G, Moideen K, Baskaran D, Banurekha V, Nair D, Sekar G . Tuberculous Lymphadenitis Is Associated with Enhanced Baseline and Antigen-Specific Induction of Type 1 and Type 17 Cytokines and Reduced Interleukin-1β (IL-1β) and IL-18 at the Site of Infection. Clin Vaccine Immunol. 2017; 24(5). PMC: 5424238. DOI: 10.1128/CVI.00045-17. View

14.

Etna M, Giacomini E, Severa M, Coccia E . Pro- and anti-inflammatory cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin Immunol. 2014; 26(6):543-51. DOI: 10.1016/j.smim.2014.09.011. View

15.

Hunter C . New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005; 5(7):521-31. DOI: 10.1038/nri1648. View

16.

Wozniak T, Ryan A, Triccas J, Britton W . Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun. 2005; 74(1):557-65. PMC: 1346624. DOI: 10.1128/IAI.74.1.557-565.2006. View

17.

Mendez-Samperio P . Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease. Int J Infect Dis. 2009; 14(5):e366-71. DOI: 10.1016/j.ijid.2009.06.022. View

18.

Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y . DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine. 2005; 24(8):1191-204. DOI: 10.1016/j.vaccine.2005.08.103. View

19.

Yan N, Chen Z . Intrinsic antiviral immunity. Nat Immunol. 2012; 13(3):214-22. PMC: 3549670. DOI: 10.1038/ni.2229. View

20.

Cooper A . Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009; 27:393-422. PMC: 4298253. DOI: 10.1146/annurev.immunol.021908.132703. View